Last $80.07 USD
Change Today +1.93 / 2.47%
Volume 1.6M
QCOR On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 04/23/14 All times are local (Market data is delayed by at least 15 minutes).

questcor pharmaceuticals (QCOR) Snapshot

Open
$77.44
Previous Close
$78.14
Day High
$80.24
Day Low
$76.75
52 Week High
04/9/14 - $85.69
52 Week Low
04/26/13 - $28.93
Market Cap
4.9B
Average Volume 10 Days
3.0M
EPS TTM
$4.86
Shares Outstanding
60.6M
EX-Date
06/27/14
P/E TM
16.5x
Dividend
$1.20
Dividend Yield
1.44%
Current Stock Chart for QUESTCOR PHARMACEUTICALS (QCOR)

questcor pharmaceuticals (QCOR) Related Businessweek News

No Related Businessweek News Found

questcor pharmaceuticals (QCOR) Details

Questcor Pharmaceuticals, Inc., a biopharmaceutical company, provides drugs for the treatment of autoimmune and inflammatory disorders. The company primarily offers H.P. Acthar Gel, an injectable drug to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus; as exacerbation or maintenance therapy in various cases of systemic lupus erythematosus and systemic dermatomyositis; and as adjunctive therapy for short-term administration in psoriatic arthritis, rheumatoid arthritis, and ankylosing spondylitis. Its H.P. Acthar Gel is also used for the treatment of acute exacerbations of multiple sclerosis in adults; and as monotherapy for the treatment of infantile spasms in infants and children under two years of age. The company sells its product primarily to specialty pharmacies. Questcor Pharmaceuticals, Inc. was founded in 1990 and is headquartered in Anaheim, California.

703 Employees
Last Reported Date: 02/26/14
Founded in 1990

questcor pharmaceuticals (QCOR) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: $800.0K
Chief Operating Officer
Total Annual Compensation: $500.0K
Chief Technical Officer and Executive Vice Pr...
Total Annual Compensation: $450.0K
Executive Vice President of Strategic Affairs...
Total Annual Compensation: $440.0K
Chief Scientific Officer
Total Annual Compensation: $500.0K
Compensation as of Fiscal Year 2012.

questcor pharmaceuticals (QCOR) Key Developments

Questcor Announces Quarterly Cash Dividend Payable or About July 8, 2014

Questcor Pharmaceuticals, Inc. announced that its Board of Directors has declared a quarterly cash dividend of $0.30 per share ($1.20 per share on an annual basis). The dividend will be paid on or about July 8, 2014 to shareholders of record at the close of business on July 1, 2014. The Company previously announced the declaration of a quarterly cash dividend of $0.30 per share which will be paid on or about April 25, 2014 to shareholders of record at the close of business on April 18, 2014.

Mallinckrodt plc, Questcor Pharmaceuticals, Inc. - M&A Call

To discuss merger agreement under which Mallinckrodt will acquire Questcor

Questcor Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2013

Questcor Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the fourth quarter and year ended December 31, 2013. For the quarter, net sales were $242,881,000 against $160,532,000 a year ago. Income from operations was $136,334,000 against $94,760,000 a year ago. Income before income taxes was $138,822,000 against $94,927,000 a year ago. Net income was $89,983,000 or $1.44 per diluted share against $61,940,000 or $1.03 per diluted share a year ago. Adjusted net income was $103,697,000 or $1.67 per diluted share against $65,705,000 or $1.09 per diluted share a year ago. The increase in Net Sales were driven by the expanded usage of H.P. Acthar(R) Gel (repository corticotropin injection) in multiple therapeutic areas. The most significant increase in Net Sales were driven by rheumatologists prescribing Acthar for patients suffering from dermatomyositis, polymyositis, rheumatoid arthritis, and systemic lupus erythematosus. The increase in Net Sales were also driven by the increased prescribing of Acthar by nephrologists in the treatment of proteinuria associated with nephrotic syndrome (NS) and by neurologists in the treatment of multiple sclerosis (MS) relapses and infantile spasms (IS). Operating cash flow during the fourth quarter was $106 million, driven primarily by net income of $90 million in the quarter. Return on equity was 91% in the fourth quarter. For the year, net sales were $798,929,000 against $509,292,000 a year ago. Income from operations was $439,838,000 against $296,527,000 a year ago. Income before income taxes was $439,540,000 against $297,230,000 a year ago. Net income was $292,609,000 or $4.76 per diluted share against $197,675,000 or $3.14 per diluted share a year ago. Adjusted net income was $336,514,000 or $5.48 per diluted share against $209,644,000 or $3.33 per diluted share a year ago. Net cash flows provided by operating activities were $337,778,000 against $219,037,000 a year ago. Purchase of property, equipment and leasehold improvements were $3,536,000 against $1,065,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
QCOR:US $80.07 USD +1.93

QCOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Boston Scientific Corp $13.69 USD -0.06
CR Bard Inc $136.59 USD -4.52
Novartis AG SFr.75.50 CHF -0.75
Sanofi €77.25 EUR +0.20
View Industry Companies
 

Industry Analysis

QCOR

Industry Average

Valuation QCOR Industry Range
Price/Earnings 16.4x
Price/Sales 5.8x
Price/Book 11.5x
Price/Cash Flow 16.0x
TEV/Sales 5.6x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUESTCOR PHARMACEUTICALS, please visit www.questcor.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.